BioXcel Therapeutics (BTAI) Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. SPY
9. EVMN
10. AAPL

Go back to BioXcel Therapeutics (BTAI) Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
(NASDAQ: BTAI) Delayed: 0.07 --0 (-0%)
Previous Close $0.07    52 Week High $ 
Open $0.07    52 Week Low $ 
Day High $0.07    P/E N/A 
Day Low $0.07    EPS $ 
Volume 5,049,998